Michele Baccarani
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 677
- Chronic Myeloid Leukemia Treatments 479
- Acute Myeloid Leukemia Research 139
- Multiple Myeloma Research and Treatments 81
- Genetics 463
- Chronic Lymphocytic Leukemia Research 405
- Myeloproliferative Neoplasms: Diagnosis and Treatment 60
- Co-authors
- Andreas Hochhaus (57 shared papers)Sante Tura (137 shared papers)Giovanni Martinelli (199 shared papers)Jörge E. Cortes (65 shared papers)Hagop Kantarjian (60 shared papers)Gianantonio Rosti (109 shared papers)Giuseppe Saglio (72 shared papers)Francisco Cervantes (16 shared papers)
- Journals
- Blood (315 papers)Leukemia (51 papers)British Journal of Haematology (40 papers)Haematologica (40 papers)Annals of Hematology (18 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
Michele Baccarani
909 papers receiving 49.3k citations
Michele Baccarani's Hit Papers
Peers
Comparison fields: 5 of 159
- Hematology 36.8k
- Genetics 21.6k
- Rheumatology 12.1k
- Pathology and Forensic Medicine 6.0k
- Oncology 8.5k
Countries citing papers authored by Michele Baccarani
This map shows the geographic impact of Michele Baccarani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Baccarani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Baccarani more than expected).
Fields of papers citing papers by Michele Baccarani
This network shows the impact of papers produced by Michele Baccarani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Baccarani. The network helps show where Michele Baccarani may publish in the future.
Co-authors
The 25 scholars most cited alongside Michele Baccarani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 934 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2003 | 2905 |
| 2 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Hit paper breakdown → | 2006 | 2851 |
| 3 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Hit paper breakdown → | 2013 | 1614 |
| 4 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1290 |
| 5 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 1050 |
| 6 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 974 |
| 7 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 8 | Prognostic discrimination in "good-risk" chronic granulocytic leukemia Hit paper breakdown → | 1984 | 842 |
| 9 | Prognostic discrimination in "good-risk" chronic granulocytic leukemia Hit paper breakdown → | 1984 | 770 |
| 10 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Hit paper breakdown → | 2016 | 756 |
| 11 | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Hit paper breakdown → | 2010 | 716 |
| 12 | 2006 | 515 | |
| 13 | 2006 | 501 | |
| 14 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hit paper breakdown → | 2011 | 497 |
| 15 | Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Hit paper breakdown → | 2018 | 454 |
| 16 | BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet Hit paper breakdown → | 2011 | 444 |
| 17 | 2011 | 433 | |
| 18 | 2006 | 430 | |
| 19 | 2003 | 407 | |
| 20 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Hit paper breakdown → | 2016 | 404 |
About Michele Baccarani
Michele Baccarani is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 934 papers that have together received 51.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (479 papers), Chronic Lymphocytic Leukemia Research (405 papers), Eosinophilic Disorders and Syndromes (172 papers), Acute Lymphoblastic Leukemia research (161 papers), Acute Myeloid Leukemia Research (139 papers), Lymphoma Diagnosis and Treatment (109 papers), Multiple Myeloma Research and Treatments (81 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (60 papers). The work is most often cited by research in Hematology (36.8k citations), Genetics (21.6k citations), Rheumatology (12.1k citations), Pathology and Forensic Medicine (6.0k citations) and Oncology (8.5k citations). Michele Baccarani has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Andreas Hochhaus, Sante Tura, Giovanni Martinelli, Jörge E. Cortes, Hagop Kantarjian, Gianantonio Rosti, Giuseppe Saglio, Francisco Cervantes, Simona Soverini and Renato Fanin. Their work appears in journals such as Blood, Leukemia, British Journal of Haematology, Haematologica and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.